Hi all 

here’s a quick update.

Elaine will be having her first Enhertu treatment next Tuesday which we will be paying around £10,000 for the privilege of trying to keep Elaine alive.

We are still fighting to have this drug funded by the NHS or receive it on compassionate grounds from the drug company who make it.Unfortunately we are still being turned down on all fronts.

Below is an email sent to our Oncologist from  who is  at Daiichi Sankyo Europe GmbHDaiichi Sankyo Europe GmbH United Kingdom

Dear Dr Haider,

It was nice to talk to you this morning.

Following our discussion I had a catch with the HO team but sadly there is no change in DS & AZ compassionate use for T-Dxd.

We are prioritising drug supply to our ongoing clinical development trials and to the approved indications globally. Therefore currently, we are not offering access to trastuzumab deruxtecan (Enhertu) under a compassionate use/early access programme for this indication in your country. We continue to evaluate EAP and alternative access opportunities for patients who have no other treatment options and will communicate any decisions as they are made.

For information on ongoing clinical trials please refer to  https://clinicaltrials.gov/  . 

I am so sorry I could not provide any favourable news on this occasion.

Please do not hesitate to contact for any additional information.

Kind Regards

From the email it’s obvious Daiichi Sankyo and AstraZeneca  don’t have a single ounce of compassion and have zero interest in helping a cancer patient to have the chance of living.

Pease remember the Enhertu is the drug our Oncologist has said is the best drug to treat Elaine’s HER2 mutations and is being used in other countries worldwide for lung cancer also supplied by Daiichi Sankyo/AstraZeneca. 

Thank you all for your continuous support.

Elaine and Chris